Related references
Note: Only part of the references are listed.Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice
M. Nagashima et al.
DIABETOLOGIA (2011)
Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study
Christopher D. Williams et al.
GASTROENTEROLOGY (2011)
Pathology of the liver in obese and diabetic ob/ob and db/db mice fed a standard or high-calorie diet
Viviane Trak-Smayra et al.
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY (2011)
Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase
Shani Ben-Shlomo et al.
JOURNAL OF HEPATOLOGY (2011)
Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced bya high-fat diet in nonalcoholic steatohepatitis
Gianluca Svegliati-Baroni et al.
LIVER INTERNATIONAL (2011)
GLP-1 Analogs Reduce Hepatocyte Steatosis and Improve Survival by Enhancing the Unfolded Protein Response and Promoting Macroautophagy
Shvetank Sharma et al.
PLOS ONE (2011)
GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice
Eva Tomas et al.
REGULATORY PEPTIDES (2011)
Depletion of Liver Kupffer Cells Prevents the Development of Diet-Induced Hepatic Steatosis and Insulin Resistance
Wan Huang et al.
DIABETES (2010)
Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults With Type 2 Diabetes
Mariana Lazo et al.
DIABETES CARE (2010)
Glucagon-Like Peptide-1 Receptor Knockout Mice Are Protected from High-Fat Diet-Induced Insulin Resistance
Julio E. Ayala et al.
ENDOCRINOLOGY (2010)
Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has a Direct Role in Decreasing Hepatic Steatosis In Vitro by Modulating Elements of the Insulin Signaling Pathway
Nitika Arora Gupta et al.
HEPATOLOGY (2010)
High-Fructose, Medium Chain Trans Fat Diet Induces Liver Fibrosis and Elevates Plasma Coenzyme Q9 in a Novel Murine Model of Obesity and Nonalcoholic Steatohepatitis
Rohit Kohli et al.
HEPATOLOGY (2010)
Leptin Promotes the Myofibroblastic Phenotype in Hepatic Stellate Cells by Activating the Hedgehog Pathway
Steve S. Choi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
NASH Thiazolidinediones for NASH-one pill doesn't fix everything
Brent A. Neuschwander-Tetri
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2010)
Pathology of nonalcoholic fatty liver disease
Elizabeth M. Brunt
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2010)
Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status
Lance L. Stein et al.
ADVANCES IN THERAPY (2009)
Epidemiology and Natural History of Non-Alcoholic Steatohepatitis
Curtis K. Argo et al.
CLINICS IN LIVER DISEASE (2009)
Nutritional Model of Steatohepatitis and Metabolic Syndrome in the Ossabaw Miniature Swine
Lydia Lee et al.
HEPATOLOGY (2009)
Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent
Laura H. Tetri et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2008)
Animal models of NASH: Getting both pathology and metabolic context right
Claire Z. Larter et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2008)
A rodent model of NASH with cirrhosis, oval cell proliferation and hepatocellular carcinoma
Vicencia M. R. de Lima et al.
JOURNAL OF HEPATOLOGY (2008)
Gene Therapy for Diabetes: Metabolic Effects of Helper-dependent Adenoviral Exendin 4 Expression in a Diet-induced Obesity Mouse Model
Susan L. Samson et al.
MOLECULAR THERAPY (2008)
The Epidemiology of Nonalcoholic Fatty Liver Disease: A Global Perspective
Mariana Lazo et al.
SEMINARS IN LIVER DISEASE (2008)
Effects of Weight Loss on Nonalcoholic Fatty Liver Disease
Nila Rafiq et al.
SEMINARS IN LIVER DISEASE (2008)
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
David C. Klonoff et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Biological activity of AC3174, a peptide analog of exendin-4
Diane M. Hargrove et al.
REGULATORY PEPTIDES (2007)
Protection of pancreatic β-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress;: in vivo and in vitro studies
Shin Tsunekawa et al.
JOURNAL OF ENDOCRINOLOGY (2007)
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Renata Belfort et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
GLP-1 receptor activation improves β cell function and survival following induction of endoplasmic reticulum stress
Bernardo Yusta et al.
CELL METABOLISM (2006)
Incretin mimetics as a novel therapeutic option for hepatic steatosis
Maarten E. Tushuizen et al.
LIVER INTERNATIONAL (2006)
Effect of calorie restriction with or without exercise on insulin sensitivity, β-cell function, fat cell size, and ectopic lipid in overweight subjects
D. Enette Larson-Meyer et al.
DIABETES CARE (2006)
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice
XK Ding et al.
HEPATOLOGY (2006)
WFS1 is a novel component of the unfolded protein response and maintains homeostasis of the endoplasmic reticulum in pancreatic β-cells
SG Fonseca et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver
H Honda et al.
HEPATOLOGY (2002)
Leptin in hepatic fibrosis:: Evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice
NK Saxena et al.
HEPATOLOGY (2002)
Share Paper
